Bringing pharmaceutical formulations to commercial fruition across the United Kingdom and global markets demands an agile regulatory framework that reflects post-Brexit realities and international harmonisation standards. As an accomplished Regulatory Affairs & Dossier Development Company in UK, KMS Pharma provides end-to-end scientific, analytical, and operational oversight for pharmaceutical sponsors, generic drug developers, and marketing authorisation holders (MAHs).
Our multidisciplinary team bridges laboratory-scale development and complex dossier publishing. By harmonising Chemistry, Manufacturing, and Controls (CMC) technical files with local health authority expectations, we eliminate dossier validation rejections, streamline assessment clock cycles, and safeguard your commercial launch schedules across the UK, EU, US, and beyond.
Expert Regulatory Dossier Preparation in UK
Navigating modern health authority evaluations requires high-quality regulatory dossier preparation in UK that aligns raw experimental data with stringent ICH guidelines. Whether compiling dossiers for novel formulations, line extensions, or generic drug dossiers, scientific consistency across administrative, clinical, and quality components is mandatory.
At KMS Pharma, our dossier preparation process begins with thorough gap analyses of source analytical files, process validation protocols, and stability records. We convert disparate laboratory documentation into an integrated scientific narrative, pre-emptively addressing potential assessor queries regarding dissolution kinetics, impurity profiles, and microbial limits.
Data Feasibility Audit
Scrutinise technical source files, analytical method transfers, and batch records to identify compliance discrepancies before file construction.
Module Assembly
Author transparent, evidence-based quality summaries, clinical overviews, and Module 3 CMC sections aligned with target market guidance.
Post-Filing Governance
Coordinate ongoing variations, annual updates, pharmacovigilance reports, and site transfers to maintain product compliance across its lifespan.
Strategic regulatory documentation is not simply a compliance hurdle; it is a commercial asset that protects development capital and accelerates market entry.
MHRA Marketing Authorisation in UK
Securing an MHRA marketing authorisation in UK requires navigating dedicated national procedures, the Windsor Framework implications for Northern Ireland, and modern accelerated review options. Pharmaceutical companies must choose the ideal submission route to ensure seamless nationwide commercial distribution.
KMS Pharma provides strategic guidance and operational execution across all MHRA application models, including the International Recognition Procedure (IRP), the Innovative Licensing and Access Pathway (ILAP), and standard National Submissions. We manage UK-specific documentation, local packaging artwork compliance, Summary of Product Characteristics (SmPC) alignment, and Patient Information Leaflet (PIL) readability testing.
Route Optimisation & Strategy
Evaluate reference products and determine the optimal pathway—such as national, rolling review, or the International Recognition Procedure (IRP) utilising trusted reference regulators.
UK-Specific Module 1 Compilation
Prepare bespoke administrative files, UK territorial coverage declarations, Qualified Person for Pharmacovigilance (QPPV) statements, and Summary of Pharmacovigilance Systems (SPS).
MHRA Portal Submission & Assessment Management
Execute portal transmission, validate electronic submission acknowledgement, and oversee the assessment timetable through to final marketing authorisation issuance.
CTD Dossier Preparation in UK
The Common Technical Document (CTD) format remains the cornerstone of modern pharmaceutical registrations. Flawless CTD dossier preparation in UK demands granular attention to document architecture, ensuring that every claim in Modules 2, 4, and 5 is traceable to raw study protocols and batch manufacturing evidence in Module 3.
Our regulatory scientists construct cohesive CTD dossiers that satisfy international assessors. By establishing clear cross-referencing and consistent technical data throughout all modules, we minimise the administrative queries and validation holds that often delay early review stages.
Module 1 Administrative Documentation: Adapt region-specific legal paperwork, application forms, manufacturer licences, and paediatric investigation plans (PIPs).
Module 2 Summaries & Overviews: Craft authoritative Quality Overall Summaries (QOS), Clinical Overviews, and Non-Clinical Overviews that capture technical nuances.
Module 3 Quality (CMC): Consolidate detailed drug substance (API) characterisation, excipient controls, drug product formulation development, and stability studies.
Modules 4 & 5 Safety & Efficacy: Structure non-clinical safety studies and clinical bioequivalence or pharmacokinetic trial reports with transparent statistical evaluations.
eCTD Dossier in UK Publishing & Lifecycle Management
Modern regulatory submissions require error-free electronic compilation. Building an eCTD dossier in UK is a specialised discipline requiring rigorous XML backbone creation, strict leaf-attribute compliance, and complete PDF hyperlinking verification against current MHRA and EMA electronic submission validation criteria.
KMS Pharma utilizes dedicated eCTD publishing software and validation engines to prepare clean, fully compliant electronic sequences. From initial sequence (0000) through supplementary responses, variations, and renewals, our team guarantees that your electronic submissions pass automated validation on first pass.
XML Backbone Integrity
Build and validate regional XML backbones conforming to MHRA and ICH DTD specifications, preventing checksum and file-naming errors.
Granular Hyperlinking
Implement comprehensive inter-document and intra-document bookmarks, active hyperlinks, and font-embedding for efficient reviewer navigation.
Lifecycle Tracking
Manage sequential versioning with accurate operational attributes (New, Replace, Delete, Append) across multi-year product submission histories.
EU Dossier for Generic Medicines in UK Strategies
Commercial pharmaceutical success frequently requires parallel registration across the UK and the European Union. Managing an EU dossier generic in UK context requires expertise in post-Brexit regulatory divergence, European reference medicinal products (EU RMP), and national procedural nuances across EU Member States.
KMS Pharma prepares dual-track dossiers capable of simultaneously satisfying the MHRA and the European Medicines Agency (EMA). We guide sponsors through the Decentralised Procedure (DCP), Mutual Recognition Procedure (MRP), and Centralised Procedure, ensuring bioequivalence studies and quality datasets meet European Committee for Medicinal Products for Human Use (CHMP) standards.
Reference Product Evaluation: Identify suitable European Reference Medicinal Products and confirm proof of bioequivalence or bio-waiver eligibility.
RMS/CMS Strategic Engagement: Assist with Reference Member State (RMS) selection, pre-submission dialogues, and timetable management.
Dual-Format Dossier Harmonisation: Adapt single dossier master files for rapid cross-submission to both UK MHRA and individual European national health agencies.
CMC Regulatory Consultant in UK
Chemistry, Manufacturing, and Controls (CMC) technical files encounter the highest proportion of health authority deficiencies. An experienced CMC regulatory consultant in UK provides technical governance to ensure that chemical characterisation, manufacturing processes, analytical methods, and packaging systems are completely defensible.
Our CMC consultants work directly with manufacturing and laboratory teams. We review Active Pharmaceutical Ingredient (API) Drug Master Files (DMF/ASMF), formulate scientifically justified finished product specifications, evaluate container closure integrity, and establish shelf-life parameters supported by ICH Q1A stability testing.
Drug Substance (S-Part)
Evaluate synthetic pathways, critical process parameters (CPPs), starting material justifications, genotoxic impurity controls, and polymorphism data.
Drug Product (P-Part)
Document pharmaceutical development, Quality by Design (QbD) parameters, scale-up protocols, batch analyses, and dissolution profiling.
Method Validation
Verify that analytical procedures for assay, related substances, and residual solvents strictly satisfy ICH Q2(R1/R2) validation requirements.
ANDA Filing Support in UK for US Market Entry
Expanding pharmaceutical products into the United States requires navigating the complex legal and scientific requirements of an Abbreviated New Drug Application (ANDA). UK-based developers targeting the US market must align their development programmes with US FDA 21 CFR standards and GDUFA performance goals.
KMS Pharma provides specialised ANDA filing support in UK, bridging European development data with US FDA expectations. We coordinate Quality Overall Summary (QOS) development, evaluate Paragraph IV patent certification requirements, map dissolution profiles against FDA Office of Generic Drugs (OGD) databases, and ensure Electronic Submissions Gateway (ESG) readiness.
US Reference Listed Drug (RLD) Benchmarking: Guide reverse engineering and bioequivalence study designs matching US reference standards.
FDA Pre-Assigned Numbers & DMF Coordination: Facilitate US FDA facility establishment registrations, NDC assignments, and DMF letters of access (LOA).
Controlled Correspondence Management: Draft, submit, and manage formal inquiries with the US FDA regarding development queries and bioequivalence protocols.
TGA Registration for Generic Medicines in UK Programmes
Australia's Therapeutic Goods Administration (TGA) maintains a rigorous, internationally respected evaluation framework. For UK and global pharmaceutical teams, coordinating TGA registration generics in UK workflows allows organisations to capitalise on existing Commonwealth regulatory similarities and shared ICH quality standards.
KMS Pharma handles complete TGA Category 1 generic medicine applications. We manage Module 1 Australian-specific paperwork, Good Manufacturing Practice (GMP) clearance verification for overseas manufacturing sites, bioequivalence summary preparations, and product information/consumer medicine information (PI/CMI) development.
Comparable Overseas Regulators
Leverage the TGA's COR pathways using prior MHRA or EMA evaluation reports to expedite Australian evaluation timelines.
Site Clearance Support
Coordinate evidence packages to obtain TGA GMP clearance for external active ingredient and finished dosage manufacturing facilities.
PI & CMI Formatting
Draft compliant Product Information and Consumer Medicine Information documents aligned with the Australian therapeutic register standards.
Rapid Deficiency Response Support in UK
Receiving Requests for Further Information (RFI), Questions (LoQ), or Complete Response Letters (CRL) from authorities like the MHRA, EMA, or FDA places commercial timelines under severe pressure. Addressing deficiencies requires an evidence-based, scientifically reasoned defense that directly satisfies the reviewer's technical concerns.
KMS Pharma provides rapid, structured deficiency response support in UK. We evaluate assessor critique, assess whether supplementary laboratory experimentation or statistical justification is required, author formal technical response documents, and update relevant dossier modules within strict clock-stop deadlines.
Forensic Question Review & Triage
Deconstruct health authority queries to identify root scientific concerns and outline a compliant, realistic remediation strategy.
Technical Data Generation & Justification
Coordinate with laboratories and production teams to gather supporting batch data, validation reports, or comparative dissolution curves.
Response Authoring & Sequence Publishing
Author formal point-by-point response narratives, update impacted eCTD sections, and submit a fully validated supplementary sequence.
Dossier Licensing & Out-Licensing in UK
Maximising return on investment across pharmaceutical developments requires proactive portfolio commercialisation. Structuring dossier licensing out-licensing in UK arrangements allows developers to monetise regulatory assets while granting regional marketing partners access to approved or submission-ready dossiers.
KMS Pharma assists pharmaceutical companies in evaluating, positioning, and documenting regulatory dossiers for commercial transactions. We conduct technical due diligence, assess dossier regulatory compliance, audit data exclusivity periods, and support commercial partners with smooth marketing authorisation transfers and variation filings.
Regulatory Due Diligence: Conduct independent audits of dossiers to identify data integrity issues or technical gaps prior to acquisition or out-licensing.
Market Feasibility Review: Assess the target territory suitability of existing dossiers, detailing necessary national variations or supplementary studies.
Authorisation Transfers: Execute seamless Change of Ownership applications (Marketing Authorisation Transfers) with the MHRA and European agencies.
Ready Dossiers for Licensing in UK
Sourcing fully compiled, validated dossiers is the fastest path to expanding a commercial drug portfolio. Pharmaceutical distributors and marketers exploring ready dossiers for licensing in UK require complete, audit-tested documentation that supports immediate submission and swift market commercialisation.
KMS Pharma connects commercial partners with developed, high-quality generic and specialty dossiers across various therapeutic classes. Our technical team ensures that all licensing candidates are fully documented with validated analytical methods, cGMP manufacturing support, and complete eCTD packages ready for local review.
Solid Oral Dosages
Immediate-release and modified-release tablets and capsules across cardiovascular, CNS, pain management, and anti-infective categories.
Injectables & Parenterals
Sterile liquid fills, lyophilised vials, and ophthalmic preparations supported by validated aseptic processes and container closure integrity data.
Topical & Semi-Solid Products
Formulations with in-vitro permeation testing (IVPT) and rheological profiling suited for dermatology and local therapeutic indications.
Accelerate Your UK & Global Regulatory Milestones
Whether preparing an MHRA marketing authorisation, publishing a multi-region eCTD sequence, addressing complex CMC deficiencies, or exploring dossier licensing partnerships, KMS Pharma provides the regulatory authority and scientific insight your team requires.
Schedule a Regulatory Consultation